Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.56 |
| ▸ | APP | P05067 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31295107 | 1.00 | HTR2A (0.69) | HTR2ASLC6A4APPDRD2ADRA1D | |
| SCHEMBL5097763 | 1.00 | HTR2A (0.69) | HTR2ASLC6A4APPDRD2ADRA1D | |
| Lithium Ion SCHEMBL31530810 | 0.97 | HTR2A (0.66) | HTR2ASLC6A4APPDRD2ADRA1D | |
| SCHEMBL2904310 | 0.91 | HTR2A (0.64) | HTR2ASLC6A4APPDRD2ADRA1D | |
| SCHEMBL30275187 | 0.91 | HTR2A (0.64) | HTR2ASLC6A4APPDRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL6248133 | 0.90 | HTR2C (0.63) | HTR2ASLC6A4APPDRD2ADRA1D | |
| SCHEMBL5453495 | 0.88 | SLC6A4 (0.56) | HTR2ASLC6A4APPHTR2CADRB2 | |
| SCHEMBL31295173 | 0.88 | HTR2A (0.59) | HTR2ASLC6A4APPDRD2ADRA1D | |
| SCHEMBL28316012 | 0.82 | SLC6A4 (0.56) | HTR2ASLC6A4APPHTR2CADRB2 | |
| SCHEMBL1720378 | 0.82 | HTR2A (0.48) | HTR2ASLC6A4APPHTR2CADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1312148-C | Isochroman compounds for treatment of CNS disorders | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| CN-1620447-A | Isochroman compounds for treatment of cns disorders | LILLY CO ELI (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1409476-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003006455-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| US-5929072-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-07-27 | — | — | US | disclosed |
| CN-1223650-A | Piperidines and pyrrolidines | MERCK PATENT GMBH (DE) | 1999-07-21 | — | — | CN | disclosed |
| WO-1999010346-A1 | BENZOTHIADIAZINYL-INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| EP-0898569-A1 | PIPERIDINES AND PYRROLIDINES | MERCK PATENT GmbH (DE) | 1999-03-03 | — | — | EP | disclosed |
| EP-0897921-A1 | Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands | ELI LILLY AND COMPANY LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
| WO-1997040038-A1 | PIPERIDINES AND PYRROLIDINES | MERCK PATENT GMBH (DE) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | HTR2A 5/4885SLC6A4 33/4885APP 1709/4885 |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | HTR2A 131/4885SLC6A4 506/4885APP 2302/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR2A 2038/4885SLC6A4 1958/4885APP 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.